glp 1 drugs kidney disease GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity Glucagon-Like Peptide-1 Receptor Agonist Use

[DOI] [PubMed] [Google Scholar] 126.Barbieri M., Marfella R., Esposito A., Rizzo M.R., Angellotti E., Mauro C., Siniscalchi M., Chirico F., Caiazzo P., Furbatto F., et al

[DOI] [PubMed] [Google Scholar] 249.Ahrn B., et al

Based on current data predicting liver outcomes by fibrosis stage, patients with stages F2-F4 are considered likely to benefit from antifibrotic medication, often seen as a signal to initiate drug intervention

In December 2025, the FDA also expanded the Mounjaro indication to include paediatric patients aged ten and over with type 2 diabetes, following results from the SURPASS-PEDS trial

GLP-1 Effects on Bone Metabolism Pre-Clinical Studies Several animal models were conducted to demonstrate molecular signaling pathways of GLP-1 agonists

Semaglutide Semaglutide is the active ingredient in brand-name drugs Ozempic, Wegovy, and Rybelsus